Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation Study of New Compounds With Potential Use in Schizophrenia
NCT00916201 · Central Institute of Mental Health, Mannheim · PHASE1 · withdrawn · last registry update 2025-03-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of funding” | – | Registry record, Central Institute of Mental Health, Mannheim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-04Results posted on the registry: University of Virginia, a drug against INSR (NCT06111508)
- 2025-09-10Phase 3 first posted: Gan & Lee Pharmaceuticals., GZR4 + Insulin Icodec group (NCT07165223)
- 2025-09-08Also stopped (terminated): Sanofi, Insulin glargine 300 U/mL + Insulin degludec 100 U/mL (NCT05552859)
- 2025-08-26Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin Glargine 100U/mL (NCT04760626)
- 2025-07-22Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT07076199)
- 2025-07-17Phase 3 first posted: Geropharm, GP40321 + Apidra® SoloStar® (NCT07070752)
- 2025-07-02Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04880850)
- 2025-06-24Results posted on the registry: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05463744)
- 2025-06-12Results posted on the registry: Novo Nordisk A/S, insulin icodec + insulin degludec (NCT04848480)
- 2025-06-12Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04460885)
- 2025-06-03Results posted on the registry: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05275400)
- 2025-05-16Results posted on the registry: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05362058)
- 2025-04-03Results posted on the registry: Novo Nordisk A/S, IcoSema + Insulin icodec (NCT05352815)
- 2025-03-17Results posted on the registry: University of Minnesota, novolog insulin + levemir insulin (NCT02496780)
- 2025-03-17Also stopped (terminated): University of Minnesota, novolog insulin + levemir insulin (NCT02496780)
- 2025-02-20Results posted on the registry: Novo Nordisk A/S, Insulin degludec + Insulin Icodec (NCT04770532)
- 2025-01-17Results posted on the registry: Novo Nordisk A/S, IcoSema + Semaglutide 1 mg (NCT05259033)
- 2025-01-10Phase 3 first posted: Gan & Lee Pharmaceuticals., GZR4 + insulin degludec (NCT06767748)
- 2024-12-04Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Placebo insulin icodec (NCT04795531)
- 2024-11-20Also stopped (terminated): Astellas Pharma Inc, OSI-906 + Placebo (NCT01101906)
- 2024-10-30Results posted on the registry: Sanofi, Insulin glargine/Lixisenatide + IDegAsp (NCT05413369)
- 2024-10-18Results posted on the registry: Mannkind Corporation, Afrezza (insulin human) Inhalation Powder + insulin degludec (NCT05243628)
- 2024-10-01Phase 3 first posted: Loyola University, Insulin glargine + insulin NPH (NCT06619301)
- 2024-09-19Phase 3 first posted: University of Campinas, Brazil, NPH insulin 50 IU/mL eye drops + 0.5% methylcellulose eye drops (placebo) (NCT06601101)
- 2024-09-05Results posted on the registry: Sanofi, Insulin glargine 300 U/mL + Insulin degludec 100 U/mL (NCT05552859)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision